Neuronetics Inc. (STIM) carries a Roarable Rating of E (Strong Sell) with 31/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-01, Neuronetics Inc. (NASDAQ: STIM) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $2.38 (+5.31% 1D, market cap $181.3M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 6/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, STIM ranks #923 in composite RQD confidence.
Within the Health Care sector (Medical/Dental Instruments), STIM carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of 48.5%, and ROIC of -35.0%. By comparison, PDEX (Pro-Dex Inc.) holds a D grade (51/100 RQD, P/E 22.2x, ROIC 23.2%, cap $199.2M) and KTWO (K2 Capital Acquisition Corporation Class A Ordinary Share) posts a D+ grade (53/100 RQD, P/E N/A, ROIC —, cap $202.8M). Among the 5-stock peer group, PDEX leads on earnings multiple (22.2x) while UTMD leads on capital efficiency (26.9% ROIC).
Per STIM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001227636), Neuronetics Inc. generated $149.2M in revenue (+99.2% YoY), -$39.0M in net income, and -$20.4M in free cash flow against $141.6M in total assets and $65.8M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±12.5% realized swing band)
Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 5/9
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While STIM currently carries a cautious 31/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.52) and Max Pain ($2.50) forces dealer call-delta covering toward $3.61.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Neuronetics Inc. (STIM) surged +5.31% to $2.38, trading at 60% of its 52-week range ($0.8 – $3.44). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Beta Bionics, Inc. (BBNX) delivered earnings and revenue surprises of +1.89% and +0.96%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
MALVERN, Pa., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a leader in interventional mental health that combines its NeuroStar® TMS technology with direct patient care through the Greenbrook netwo
Integra (IART) delivered earnings and revenue surprises of +5.36% and -0.81%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +99.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on STIM today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for STIM. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Neuronetics Inc. (STIM) ranks #923 by composite RQD confidence (31/100, grade E) and #588 by equity capitalization ($181.3M). Within this direct 5-issuer industry benchmark cohort, PDEX leads on earnings valuation at 22.2x trailing P/E, while UTMD leads on capital efficiency and profitability with 26.9% ROIC and 57.1% gross margin. UTMD currently holds the highest overall quantitative score in the immediate peer group at 63/100 (C) compared with STIM at 31/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| STIM
ACTIVE
Neuronetics Inc. | E | 31/100 | — | 48.5% | -35.0% | +5.31% | $181.3M | Benchmark Subject |
| PDEX Pro-Dex Inc. | D | 51/100 | 22.2x | 29.3% | 23.2% | -2.52% | $199.2M | /pdex-vs-stim → |
| KTWO K2 Capital Acquisition Corporation Class A Ordinary Share | D+ | 53/100 | — | — | — | +0.30% | $202.8M | /ktwo-vs-stim → |
| UTMD Utah Medical Products Inc. | C | 63/100 | — | 57.1% | 26.9% | -2.96% | $212.7M | /utmd-vs-stim → |
| PROF Profound Medical Corp. | D | 47/100 | — | 70.8% | -35.0% | +1.38% | $214.1M | /prof-vs-stim → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Neuronetics Inc. (STIM) reported GAAP revenue of $149.2M (+99.2% vs. FY2024 revenue of $74.9M , and +109.1% cumulative change since FY2023) , GAAP net income of -$39.0M, operating cash flow of -$20.4M, and free cash flow of -$20.4M (+34.2% YoY). On the balance sheet, STIM closed FY2025 with $141.6M in total assets against $65.8M in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 5/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $149.2M | -$39.0M | -$20.4M | -$20.4M | $141.6M | $65.8M |
| FY2024 (FY) | 2024-12-31 | $74.9M | -$43.7M | -$31.0M | -$31.0M | $140.9M | $55.2M |
| FY2023 (FY) | 2023-12-31 | $71.3M | -$30.2M | -$32.0M | -$32.0M | — | — |
As of 2026-11-01, Neuronetics Inc. (NASDAQ: STIM) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $2.38 (+5.31% 1D, market cap $181.3M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 6/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, STIM ranks #923 in composite RQD confidence.
Within the Health Care sector (Medical/Dental Instruments), STIM carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of 48.5%, and ROIC of -35.0%. By comparison, PDEX (Pro-Dex Inc.) holds a D grade (51/100 RQD, P/E 22.2x, ROIC 23.2%, cap $199.2M) and KTWO (K2 Capital Acquisition Corporation Class A Ordinary Share) posts a D+ grade (53/100 RQD, P/E N/A, ROIC —, cap $202.8M). Among the 5-stock peer group, PDEX leads on earnings multiple (22.2x) while UTMD leads on capital efficiency (26.9% ROIC).
Per STIM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001227636), Neuronetics Inc. generated $149.2M in revenue (+99.2% YoY), -$39.0M in net income, and -$20.4M in free cash flow against $141.6M in total assets and $65.8M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
STIM last traded at $2.38 (+5.31% on volume of 832,306 shares), positioning the stock -5.56% below its 50-day simple moving average ($2.52) and +27.27% above its 200-day simple moving average ($1.87). Across its 52-week range of $0.80 to $3.44, STIM sits at the 59.8% percentile with a 14-day RSI of 50.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.08 to $2.68).
Why STIM Stock surged +5.31% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Paper Trading Arena account.